English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The function of  Vasohibin-1  ( VASH1 ) in human cancer has not been thoroughly or comprehensively examined. Here, we identified the tumor suppressor part of  VASH1  across cancers, including epithelial ovarian tumors. Our study carefully contrasted the expression of VASH1 in pancancer and nontumorous tissues in a public database to explore its regulatory role in clinical prognosis, diagnosis, tumor purity, and immune cell infiltration. Next, we explored the antitumor mechanism of  VASH1  through drug sensitivity, functional enrichment, and phenotypic experiments in ovarian cancer. Research suggests that the expression of  VASH1  in neoplastic tissues is lower than that in normal tissues.  VASH1  affects the OS and RFS of several tumor types. In addition,  VASH1  expression resulted in a high OS and RFS in the diagnosis of tumor and nontumor tissues and negatively regulated tumor purity. Moreover,  VASH1  controls the tumor microenvironment by regulating immunocyte infiltration. In ovarian cancer,  VASH1  can serve as a biomarker to estimate the efficacy of chemotherapy. Functional enrichment analysis suggests that  VASH1  plays a tumor suppressor role by regulating the extracellular matrix receptor pathway.  VASH1  inhibition of the malignant phenotype of ovarian cancer cells was further confirmed by  in vivo  experiments. These results indicate that  VASH1  acts as a cancer-inhibiting factor and potential therapeutic target in ovarian cancer.

Revealing the inhibitory effect of VASH1 on ovarian cancer from multiple perspectives